Detection of Colistin Resistance in Uropathogenic Carbapenem Resistant Klebsiella pneumoniae

Background: Colistin resistance among carbapenem-resistant Klebsiella pneumoniae (CRKp) strains at an accelerated rate poses a serious global threat which limits therapeutic options. Objective: In this study, 203 laboratory-archived uropathogenic K. pneumoniae isolates were screened for carbapenem and colistin resistance. Methods: Carbapenam resistance screening was performed using combined disc test. Colistin resistance was determined for CRKp isolates, according to clinical and laboratory standards institute- European Committee on Antimicrobial Susceptibility Testing guidelines. Polymerase Chain Reaction for carbapenamase genes (blaNDM-1, blaKPC-2 and blaOXA-1) and plasmid-mediated colistin resistance genes (mcr-1-2) were performed for the resistant isolates. Results: About 30% of the CRKp isolates were resistant to colistin; 57.1% and 35.7% of the isolates carried blaNDM-1 and blaOXA-1 gene, respectively. None of the isolates showed positive for blaKPC-2 and mcr (1-2) genes. Conclusion: Colistin resistance in the absence of a plasmid borne transfer mechanism was observed among our CRKp strains. Escalating colistin resistance is a crucial obstacle in treatment of K. pneumoniae infections and repurposing their usage is important to combat and control the resistance

SARS-CoV-2 seroprevalence among the general population and healthcare workers in India, December 2020–January 2021

Background: Earlier serosurveys in India revealed seroprevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) of 0.73% in May–June 2020 and 7.1% in August–September 2020. A third serosurvey was conducted between December 2020 and January 2021 to estimate the seroprevalence of SARS-CoV-2 infection among the general population and healthcare workers (HCWs) in India. Methods: The third serosurvey was conducted in the same 70 districts as the first and second serosurveys. For each district, at least 400 individuals aged ≥10 years from the general population and 100 HCWs from subdistrict-level health facilities were enrolled. Serum samples from the general population were tested for the presence of immunoglobulin G (IgG) antibodies against the nucleocapsid (N) and spike (S1-RBD) proteins of SARS-CoV-2, whereas serum samples from HCWs were tested for anti-S1-RBD. Weighted seroprevalence adjusted for assay characteristics was estimated. Results: Of the 28,598 serum samples from the general population, 4585 (16%) had IgG antibodies against the N protein, 6647 (23.2%) had IgG antibodies against the S1-RBD protein, and 7436 (26%) had IgG antibodies against either the N protein or the S1-RBD protein. Weighted and assay-characteristic-adjusted seroprevalence against either of the antibodies was 24.1% [95% confidence interval (CI) 23.0–25.3%]. Among 7385 HCWs, the seroprevalence of anti-S1-RBD IgG antibodies was 25.6% (95% CI 23.5–27.8%). Conclusions: Nearly one in four individuals aged ≥10 years from the general population as well as HCWs in India had been exposed to SARS-CoV-2 by December 2020